1. Evaluating the Totality of Evidence

3. Content Outline

4. Local RT With ADT for Advanced Prostate Cancer Intergroup Study Final Results

5. Confirming the Benefit of RT

6. Local Therapy for Nonmetastatic Prostate Cancer -- STAMPEDE Data

7. STAMPEDE Outcomes by Tumor Volume in Metastatic Prostate Cancer

8. New Questions for Optimal Local Therapy

9. Using Docetaxel for mHSPC Insights from CHAARTED

10. Docetaxel: High-Volume Disease CHAARTED Primary Analysis

11. Docetaxel: High- vs Low-Volume Disease CHAARTED Primary Analysis

12. CHAARTED Final Analysis Low-Volume Disease

13. PUNCH Trial -- Chemotherapy in the Neoadjuvant Setting

14. LATITUDE The Role of Frontline Abiraterone in High-Risk mHSPC

15. Final LATITUDE Results

16. Abiraterone in Low-Risk/Low-Volume Disease

17. Should Low-Risk Patients Get Additional Systemic Therapy?

18. High-Risk Patients Abiraterone or Docetaxel?

19. Selecting Optimal Add-On Therapy to ADT

20. Nonmetastatic CRPC

21. AR-Targeted Therapy for Nonmetastatic CRPC

22. Earlier Treatment = Longer Time to Progression and Resistance

23. Toxicity Profiles of Anti-AR Therapies

24. Feasibility of Sequencing AR Therapies and Anti-Androgen Therapy

25. Key Questions When Patients Progress to Metastatic Disease

26. Recent Data in Radiopharmaceuticals

27. VISION Trial PSMA-Targeted Therapy for mCRPC

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)